Insight into continuous glucose monitoring: from medical basics to commercialized devices
- PMID: 37022500
- DOI: 10.1007/s00604-023-05743-w
Insight into continuous glucose monitoring: from medical basics to commercialized devices
Abstract
According to the latest statistics, more than 537 million people around the world struggle with diabetes and its adverse consequences. As well as acute risks of hypo- or hyper- glycemia, long-term vascular complications may occur, including coronary heart disease or stroke, as well as diabetic nephropathy leading to end-stage disease, neuropathy or retinopathy. Therefore, there is an urgent need to improve diabetes management to reduce the risk of complications but also to improve patient's quality life. The impact of continuous glucose monitoring (CGM) is well recognized, in this regard. The current review aims at introducing the basic principles of glucose sensing, including electrochemical and optical detection, summarizing CGM technology, its requirements, advantages, and disadvantages. The role of CGM systems in the clinical diagnostics/personal testing, difficulties in their utilization, and recommendations are also discussed. In the end, challenges and prospects in future CGM systems are discussed and non-invasive, wearable glucose biosensors are introduced. Though the scope of this review is CGMs and provides information about medical issues and analytical principles, consideration of broader use will be critical in future if the right systems are to be selected for effective diabetes management.
Keywords: Artificial intelligence; Biosensor; Continuous glucose monitoring; Diabetes.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
References
-
- International Diabetes Federation (2021) IDF Diabetes Atlas 10th edition.
-
- Gregory GA, Robinson TIG, Linklater SE et al (2022) Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol 10:741–760. https://doi.org/10.1016/S2213-8587(22)00218-2 - DOI - PubMed
-
- Marcon LMR, Fanelli CG, Calafiore R (2022) Type 1 diabetes (T1D) and latent autoimmune diabetes in adults (LADA): the difference between a honeymoon and a holiday. Case Rep Endocrinol 9363543:1–5. https://doi.org/10.1155/2022/9363543 - DOI
-
- Erlich H, Valdes AM, Noble J et al (2008) HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk analysis of the type 1 diabetes genetics consortium families. Diabetes 57:1084–1092. https://doi.org/10.2337/db07-1331 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials